Cardiovascular Research Institute of Traditional Chinese Medicine, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China,; Cardiovascular Department of Traditional Chinese Medicine, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China; Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Branch of National Clinical Research Center for Chinese Medicine Cardiology, Shanghai 201203, China.
Cardiovascular Research Institute of Traditional Chinese Medicine, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China,; Cardiovascular Department of Traditional Chinese Medicine, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China; Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Branch of National Clinical Research Center for Chinese Medicine Cardiology, Shanghai 201203, China.
Pharmacol Res. 2021 Aug;170:105743. doi: 10.1016/j.phrs.2021.105743. Epub 2021 Jun 26.
Nowadays acute myocardial infarction (AMI) is a serious cardiovascular disease threatening the human life and health worldwide. The most effective treatment is to quickly restore coronary blood flow through revascularization. However, timely revascularization may lead to reperfusion injury, thereby reducing the clinical benefits of revascularization. At present, no effective treatment is available for myocardial ischemia/reperfusion injury. Emerging evidence indicates that epigenetic regulation is closely related to the pathogenesis of myocardial ischemia/reperfusion injury, indicating that epigenetics may serve as a novel therapeutic target to ameliorate or prevent ischemia/reperfusion injury. This review aimed to briefly summarize the role of histone modification, DNA methylation, noncoding RNAs, and N-methyladenosine (mA) methylation in myocardial ischemia/reperfusion injury, with a view to providing new methods and ideas for the research and treatment of myocardial ischemia/reperfusion injury.
如今,急性心肌梗死(AMI)是一种严重威胁全球人类生命和健康的心血管疾病。最有效的治疗方法是通过血运重建迅速恢复冠状动脉血流。然而,及时的血运重建可能导致再灌注损伤,从而降低血运重建的临床获益。目前,针对心肌缺血/再灌注损伤尚无有效的治疗方法。新出现的证据表明,表观遗传调控与心肌缺血/再灌注损伤的发病机制密切相关,这表明表观遗传学可能成为改善或预防缺血/再灌注损伤的新治疗靶点。本综述旨在简要总结组蛋白修饰、DNA 甲基化、非编码 RNA 和 N6-甲基腺苷(m6A)甲基化在心肌缺血/再灌注损伤中的作用,以期为心肌缺血/再灌注损伤的研究和治疗提供新的方法和思路。